MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 14, 2013 at 11:30 AM (ET) at the Westin Grand Central in New York City. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA®, has completed Phase 3 clinical trials. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.